Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: Randomized placebo-controlled trial

AIDS

Volumn 29, Issue 3, 2014, Pages 313-321

  Dirajlal Fargo, Sahera ^a,b   Kinley, Bruce ^a   Jiang, Ying ^a   Longenecker, Chris T ^a,c   Hileman, Corrilynn O ^a,d   Debanne, Sara ^a   McComsey, Grace A ^a,b,e  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d METROHEALTH MEDICAL CENTER   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Inflammation; N terminal pro B type natriuretic peptide; Statin therapy

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYSTATIN C; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROTEINASE INHIBITOR; ROSUVASTATIN; TENOFOVIR; TRIACYLGLYCEROL; ANTIRETROVIRUS AGENT; BRAIN NATRIURETIC PEPTIDE; FLUOROBENZENE; HYPOCHOLESTEROLEMIC AGENT; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CD8+ T LYMPHOCYTE; COMMON CAROTID ARTERY; CONTROLLED STUDY; CORONARY ARTERY CALCIUM SCORE; CREATININE CLEARANCE; FEMALE; FRAMINGHAM RISK SCORE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROBENZENES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PLACEBOS; PYRIMIDINES; ROSUVASTATIN CALCIUM; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84927586480     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000547     Document Type: Article

References (44)

1. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr. Biology of the natriuretic peptides.AmJ Cardiol 2008; 101:3-8
2. Vasan RS, Benjamin EJ, LarsonMG, Leip EP,Wang TJ,WilsonPW, Levy D. Plasmanatriuretic peptides for community screening for left-ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002; 288:1252-1259
3. Galasko GI, Lahiri A, Barnes SC, Collinson P, Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?. Eur Heart J 2005; 26:2269-2276
4. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358:2107-2116
5. Ang DS, Kong CF, Kao MP, Struthers AD. Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities. Am Heart J 2009; 158:133-140
6. Laukkanen JA, Kurl S, Ala-Kopsala M, Vuolteenaho O, Ruskoaho H, Nyyssonen K, Salonen JT. Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men. Eur Heart J 2006; 27:1230-1237
7. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009; 120:2177-2187
8. Duprez DA, Neuhaus J, Tracy R, Kuller LH, Deeks SG, Orkin C, et al. N-Terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. AIDS 2011; 25:651-657
9. Mansoor A, Althoff K, Gange S, Anastos K, Dehovitz J, Minkoff H, et al. Elevated NT-pro-BNP levels are associated with comorbidities among HIV-infected women. AIDS Res Hum Retroviruses 2009; 25:997-1004
10. The Antiretroviral Therapy Cohort Collaboration: Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort, studies. Clin Infect Dis 2010; 50:1387-1396
11. Hsue PY, Hunt PW, Ho JE, Bolger AF, Martin JN, Deeks SG, Waters DD. Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail 2010; 3:132-139
12. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PloS One 2013; 8:e81355
13. Marcus JL, Leyden WA, Chao CR, Chow FC, Horberg MA, Hurley LB, et al. HIV infection and incidence of ischemic stroke. AIDS 2014; 28:1911-1919
14. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-2512
15. Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US healthcare system. J Acquir Immune Defic Synd 2012; 60:351-358
16. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173: 614-622
17. Tousoulis D, Oikonomou E, Siasos G, Chrysohoou C, Zaromitidou M, Kioufis S, et al. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis 2013; 227:367-372
18. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AMJr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.NEngl J Med 2008; 359:2195-2207
19. Stypmann J, Schubert A, Welp H, Schulte H, Assmann G, Breithardt G, Nofer JR. Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure. Clin Cardiol 2008; 31:478-481
20. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108:839-843
21. Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, Clagett B, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis 2014; 58:588-595
22. Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis 2014; 209: 1156-1164
23. Longenecker CT, Hileman CO, Funderburg NT, McComsey GA. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURNHIV trial. Clin Infect Dis 2014; 59:1148-1156
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419
25. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612
26. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847
27. Longenecker CT, Jiang Y, Orringer CE, Gilkeson RC, Debanne S, Funderburg NT, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS 2014; 28:969-977
28. Longenecker CT, Funderburg NT, Jiang Y, Debanne S, Storer N, Labbato DE, et al. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med 2013; 14:385-390
29. Bielecka-Dabrowa A, Goch JH, Mikhailidis DP, Rysz J, Maciejewski M, Banach M. The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. Med Sci Monit 2009; 15:MS12-MS23
30. Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, et al. Plasma concentration of amino-terminal probrain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009; 54:1850-1859
31. Emberson JR,NgLL, Armitage J, Bowman L, Parish S,Collins R. Nterminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.JAmColl Cardiol 2007; 49:311-319
32. Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 2006; 152:1071-1076
33. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90:254-258
34. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109:594-600
35. Dessi-Fulgheri P, Sarzani R, Tamburrini P, Moraca A, Espinosa E, Cola G, et al. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertension 1997; 15:1695-1699
36. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, et al. N-Terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005; 46:660-666
37. Chen-Tournoux A, Khan AM, Baggish AL, Castro VM, Semigran MJ, McCabe EL, et al. Effect of weight loss after weight loss surgery on plasma N-terminal pro-B-type natriuretic peptide levels. Am J Cardiol 2010; 106:1450-1455
38. Sanchez OA, Duprez DA, Bahrami H, Daniels LB, Folsom AR, Lima JA, et al. The associations between metabolic variables and NT-proBNP are blunted at pathological ranges: the multiethnic study of atherosclerosis. Metabolism 2014; 63:475-483
39. Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab 2011; 96:3242-3249
40. Scheven L, de Jong PE, Hillege HL, Lambers Heerspink HJ, van Pelt LJ, Kootstra JE, et al. High-sensitive troponin T and Nterminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. Eur Heart J 2012; 33:2272-2281
41. van Diepen S, Roe MT, Lopes RD, Stebbins A, James S, Newby LK, et al. Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. J Thromb Thrombolysis 2012; 34:106-113
42. Jensen J, Ma LP, Fu ML, Svaninger D, Lundberg PA, Hammarsten O. Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio. Clin Res Cardiol 2010; 99:445-452
43. Roy MS, Janal MN, Crosby J, Donnelly R. Markers of endothelial dysfunction and inflammation predict progression of diabetic nephropathy in African Americans with type 1 diabetes. Kidney Int 2014. Epub ahead of print
44. Matthew R, Gingo YZ, Ghebrehawariat K, Jeong JH, Chu Y, Yang Q, et al. Elevated NT-pro-BNP levels predict mortality in HIV-infected women [Abstract 723]. Topics Antiviral Med 2014:368.